EXPO Stock Analysis: Exponent | NASDAQ
Engineering & Construction | NASDAQ, USA | Market Cap: 3.013m USD | 12M Return: -15.2% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 33.9M
EPS Trend: 75.4%
Qual. Beats: 0
Rev. Trend: 95.3%
Qual. Beats: 3
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Exponent, Inc. (NASDAQ: EXPO) is a U.S.-based science and engineering consulting firm founded in 1967 and headquartered in Menlo Park, California. Originally named The Failure Group, the company rebranded in 1998 and operates through two reporting segments: Engineering and Other Scientific, and Environmental and Health. Its services span a broad multidisciplinary range, including biomechanics, biomedical engineering, civil and structural engineering, construction consulting, electrical and computer science, human factors, materials and corrosion engineering, mechanical engineering, thermal sciences, vehicle engineering, chemical regulation and food safety, ecological and biological sciences, environmental and earth sciences, and health sciences. In addition to proactive and reactive product safety work, the firm provides litigation support and technical/regulatory consulting to clients across a wide range of end markets, including chemical, construction, consumer products, energy, food and beverage, government, life sciences, insurance, manufacturing, technology, industrial equipment, and transportation. Listed in the Industrials sector under the Research & Consulting Services sub-industry, Exponents business model centers on deploying highly credentialed scientists and engineers for failure analysis, expert testimony, and regulatory advisory engagements, a niche in which billings are typically driven by hourly technical rates and project complexity rather than by volume-based metrics common to industrial peers.
- Product liability litigation drives Engineering segment revenue growth
- Tighter chemical regulations boost Environmental and Health consulting demand
- Aggressive buybacks and dividends support per-share earnings growth
| Net Income: 108.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.16 > 0.02 and ΔFCF/TA -1.08 > 1.0 |
| NWC/Revenue: 32.96% < 20% (prev 54.11%; Δ -21.15% < -1%) |
| CFO/TA 0.18 > 3% & CFO 123.5m > Net Income 108.9m |
| Net Debt (-37.5m) to EBITDA (162.0m): -0.23 < 3 |
| Current Ratio: 2.40 > 1.5 & < 3 |
| Outstanding Shares: last quarter (50.1m) vs 12m ago -2.96% < -2% |
| Gross Margin: 23.80% > 18% (prev 60.19%; Δ -36.39% > 0.5%) |
| Asset Turnover: 83.11% > 50% (prev 73.25%; Δ 9.86% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.29 (Total Current Assets 340.9m - Total Current Liabilities 142.2m) / Total Assets 687.4m |
| B: 0.99 (Retained Earnings 682.0m / Total Assets 687.4m) |
| C: 0.21 (EBIT TTM 151.9m / Avg Total Assets 725.3m) |
| D: 0.97 (Book Value of Equity 338.3m / Total Liabilities 349.0m) |
| Altman-Z'' = 7.56 = AAA |
| DSRI: 1.10 (Receivables 197.3m/166.8m, Revenue 602.8m/559.1m) |
| GMI: 2.53 (GM 60.19% / 23.80%) |
| AQI: 1.22 (AQ_t 0.30 / AQ_t-1 0.24) |
| SGI: 1.08 (Revenue 602.8m / 559.1m) |
| TATA: -0.02 (NI 108.9m - CFO 123.5m) / TA 687.4m) |
| Beneish M = -1.37 (Cap -4..+1) = D |
As of July 15, 2026, the stock is trading at USD 62.08 with a total of 491,831 shares traded. Over the past week, the price has changed by +0.02%, over one month by +8.46%, over three months by -7.62% and over the past year by -15.15%.
Current recommended Stop Loss: 57.60 (which is 7.2% or 2.1 ATR below the current price).
Exponent has received a consensus analysts rating of 3.67. Therefore, it is recommended to hold EXPO.
- StrongBuy: 1
- Buy: 0
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 81.7 | 31.6% |
P/E Trailing = 29.0187
P/E Forward = 29.3255
P/S = 5.4661
P/B = 8.9026
P/EG = 2.0325
Revenue TTM = 602.8m USD
EBIT TTM = 151.9m USD
EBITDA TTM = 162.0m USD
Long Term Debt = 74.3m USD (estimated: total debt 81.0m - short term 6.71m)
Short Term Debt = 6.71m USD (from shortTermDebt, last quarter)
Debt = 81.0m USD (from shortLongTermDebtTotal, last quarter) (leases 81.0m already included)
Net Debt = -37.5m USD (calculated: Debt 81.0m - CCE 118.6m)
Enterprise Value = 2.98b USD (3.01b + Debt 81.0m - CCE 118.6m)
Interest Coverage Ratio = unknown (Ebit TTM 151.9m / Interest Expense TTM 0.0)
EV/FCF = 26.24x (Enterprise Value 2.98b / FCF TTM 113.4m)
FCF Yield = 3.81% (FCF TTM 113.4m / Enterprise Value 2.98b)
FCF Margin = 18.81% (FCF TTM 113.4m / Revenue TTM 602.8m)
Net Margin = 18.07% (Net Income TTM 108.9m / Revenue TTM 602.8m)
Gross Margin = 23.80% ((Revenue TTM 602.8m - Cost of Revenue TTM 459.4m) / Revenue TTM)
Gross Margin QoQ = 28.61% (prev 24.32%)
Tobins Q-Ratio = 4.33 (Enterprise Value 2.98b / Total Assets 687.4m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 81.0m)
Taxrate = 28.28% (42.9m / 151.9m)
NOPAT = 108.9m (EBIT 151.9m * (1 - 28.28%))
Current Ratio = 2.40 (Total Current Assets 340.9m / Total Current Liabilities 142.2m)
Debt / Equity = 0.24 (Debt 81.0m / totalStockholderEquity, last quarter 338.3m)
Debt / EBITDA = -0.23 (Net Debt -37.5m / EBITDA 162.0m)
Debt / FCF = -0.33 (Net Debt -37.5m / FCF TTM 113.4m)
Total Stockholder Equity = 389.8m (last 4 quarters mean from totalStockholderEquity)
RoA = 15.02% (Net Income 108.9m / Total Assets 687.4m)
RoE = 27.94% (Net Income TTM 108.9m / Total Stockholder Equity 389.8m)
RoCE = 32.72% (EBIT 151.9m / Capital Employed (Equity 389.8m + L.T.Debt 74.3m))
RoIC = 20.88% (NOPAT 108.9m / Invested Capital 521.8m)
WACC = 7.33% (E(3.01b)/V(3.09b) * Re(7.53%) + D(81.0m)/V(3.09b) * Rd(0.0%) * (1-Tc(0.28)))
Discount Rate = 7.53% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -64.01 | Cagr: -1.15%
[DCF] Terminal Value 73.10% ; FCFF base≈121.7m ; Y1≈106.7m ; Y5≈86.2m
[DCF] Fair Price = 29.30 (EV 1.38b - Net Debt -37.5m = Equity 1.42b / Shares 48.5m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: 75.38 | EPS CAGR: 2.59% | SUE: -0.66 | # QB: 0
Revenue Correlation: 95.27 | Revenue CAGR: 5.71% | SUE: 0.96 | # QB: 3
EPS current Quarter (2026-06-30): EPS=0.60 | Chg30d=+0.17% | Revisions=-50% | Analysts=4
EPS next Quarter (2026-09-30): EPS=0.64 | Chg30d=+2.92% | Revisions=-50% | Analysts=4
EPS current Year (2026-12-31): EPS=2.47 | Chg30d=+0.76% | Revisions=-17% | GrowthEPS=+19.3% | GrowthRev=+11.3%
EPS next Year (2027-12-31): EPS=2.76 | Chg30d=+1.47% | Revisions=+29% | GrowthEPS=+11.8% | GrowthRev=+8.5%
[Analyst] Revisions Ratio: -31% (up=4, down=9)